Heidi Dorris, MD
Internal Medicine · Wakefield, RINPI 1639175482
Payments from drug & device makers
Across 118 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$404
- AbbVie$320
- Novo Nordisk$291
- Pfizer$240
- GSK$106
- Teva Pharmaceuticals USA, Inc.$102
- plus $694 from 20 others
What the payments were for
- Food & beverage$2,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $404 |
| AbbVie(2 entities) | 13 | $320 |
| Novo Nordisk | 14 | $291 |
| Pfizer | 16 | $240 |
| GSK | 7 | $106 |
| Teva Pharmaceuticals USA, Inc. | 8 | $102 |
| Sanofi-aventis U.S. LLC | 5 | $87 |
| Merck | 5 | $87 |
| Amgen | 3 | $68 |
| Abbott | 3 | $53 |
| Lilly USA, LLC | 2 | $50 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $30 |
| Eisai Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $27 |
| Agios Pharmaceuticals, Inc. | 1 | $27 |
| Exact Sciences | 1 | $23 |
| Viiv Healthcare Company | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Gilead | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Insmed, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$2,157 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 148 | $190,986 |
| TrulicityDulaglutide | 86 | $93,050 |
| EliquisApixaban | 84 | $72,911 |
| JardianceEmpagliflozin | 38 | $50,484 |
| MounjaroTirzepatide | 27 | $30,370 |
| WegovySemaglutide | 14 | $25,581 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,378 |
| Nurtec OdtRimegepant Sulfate | 12 | $18,542 |
| RybelsusSemaglutide | 17 | $16,842 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $12,555 |
| JanuviaSitagliptin Phosphate | 13 | $8,006 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $7,960 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,177 |
| Rosuvastatin Calcium | 281 | $6,563 |
| BreynaBudesonide/Formoterol Fumarate | 18 | $5,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Rybelsus | $291 | $233,410179 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $50 | $123,420113 claims |
| PfizerEliquis, Nurtec Odt | $240 | $91,45496 claims |
| Boehringer IngelheimJardiance | $27 | $50,48438 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $106 | $34,51660 claims |
| MerckJanuvia | $87 | $8,00613 claims |
| AstraZenecaSymbicort | $404 | $4,01414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Wakefield
- David FriedEast Greenwich$37.2M
- Gregory AllenCranston$12.2M
- Kathleen GordonJohnston$1.1M
- William BeliveauJohnson$962K
- Scott WilsonCumberland$907K
- Aaron SamuelsProvidence$751K
- Frank D'alessandroLincoln$541K
- Andrew HsuProvidence$409K
- Heinrich ElinzanoProvidence$396K
- Ari PelcovitsProvidence$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.